Is hIV protease inhibitor use during pregnancy associated with decreased progesterone levels , suggesting a potential mechanism contributing to fetal growth restriction?
Our data suggest that PI use in pregnancy may lead to lower progesterone levels that could contribute to adverse birth outcomes.
RPVE+4 significantly improves S2+3 hypertrophy compared with RPVE alone. Extending RPVE to S4 does not increase PVE-associated complications.